The company reported revenues of $443.7 million and organic growth of 3 percent, driven in large part by strength in its scientific instruments business.
Major releases were relatively sparse at ASMS as many vendors focused instead on the development of applications and workflows for their existing platforms.
The firm posted revenues of $530.5 million, with organic growth at 4 percent and acquisitions and currency effects adding 4 percent and 5 percent, respectively.
Companies in the life science tools and molecular diagnostics spaces provided updates on their businesses at the 36th annual JP Morgan Healthcare Conference this week in San Francisco.
Researchers found that 98 percent of the identifications the system provided were correct, indicating the usefulness of the platform in clinical mycology.
